Market Place
Sourcing Support
Sales growth for Cresemba & Zevtera trigger payments to Basilea
28 Jan 2025 //
GLOBENEWSWIRE
Innoviva Signs Exclusive Deal to Acquire Zevtera® U.S. Rights
16 Dec 2024 //
BUSINESSWIRE
Basilea Presents New Ceftobiprole Data At ESCMID Global 2024
03 May 2024 //
GLOBENEWSWIRE
Basilea reports new data for Zevtera presented at US IDWeek Congress 2023
17 Oct 2023 //
GLOBENEWSWIRE
Basilea announces publication of phase 3 data on ceftobiprole
28 Sep 2023 //
GLOBENEWSWIRE
Basilea announces submission of a NDA to the US FDA for antibiotic ceftobiprole
04 Aug 2023 //
GLOBENEWSWIRE
Basilea provides update on NEW to the USFDA for antibiotic ceftobiprole
18 Apr 2023 //
GLOBENEWSWIRE
ERADICATE phase 3 study results highlight the potential role of ceftobiprole
24 Oct 2022 //
GLOBENEWSWIRE
Basilea announces Zevtera (ceftobiprole) marketing authorization in Brazil
11 Jul 2022 //
GLOBENEWSWIRE
Basilea`s positive results of PIII ERADICATE study with ceftobiprole in SAB
27 Jun 2022 //
GLOBENEWSWIRE
Basilea completes patient enrollment in phase 3 study investigating ceftobiprole
10 Jan 2022 //
GLOBENEWSWIRE
Basilea announces distribution agreement with JSC Lancet
14 Jul 2021 //
GLOBENEWSWIRE
Global MRSA Drugs Market to Surpass US$ 1.3 Billion by 2026
24 Sep 2019 //
BUSINESSWIRE
Basilea bags $72m upfront from Pfizer for antifungal license
16 Jun 2017 //
PMLIVE
Basilea dumps its $190M IPO plan as the U.S. market sputters
09 Dec 2015 //
FIERCE BIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.